GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newland Pharmaceutical Co Ltd (SZSE:301277) » Definitions » Ending Cash Position

Newland Pharmaceutical Co (SZSE:301277) Ending Cash Position : ¥240.5 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Newland Pharmaceutical Co Ending Cash Position?

Newland Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥240.5 Mil.

Newland Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 (¥259.7 Mil) to Dec. 2023 (¥270.0 Mil) but then declined from Dec. 2023 (¥270.0 Mil) to Mar. 2024 (¥240.5 Mil).

Newland Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2021 (¥30.4 Mil) to Dec. 2022 (¥46.5 Mil) and increased from Dec. 2022 (¥46.5 Mil) to Dec. 2023 (¥270.0 Mil).

Newland Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Newland Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newland Pharmaceutical Co Ending Cash Position Chart

Newland Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 19.04 36.34 30.40 46.52 270.02

Newland Pharmaceutical Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 188.35 229.72 259.70 270.02 240.53

Newland Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Newland Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=46.516+223.507
=270.0

Newland Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=270.023+-29.489
=240.5

Newland Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Newland Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Newland Pharmaceutical Co (SZSE:301277) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newland Pharmaceutical Co Ltd (SZSE:301277) » Definitions » Ending Cash Position
Comparable Companies
SZSE:002923 SZSE:300436 SZSE:002750 SHSE:600829 SHSE:688373 SHSE:600594 SHSE:688799 SHSE:603538 SZSE:002864 SZSE:301201 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
East side of the south section of Weiwu Road, Henan Province, Changge, CHN, 461500
Website
http://www.newlandpharma.com
Newland Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chiral pharmaceutical intermediates.

Newland Pharmaceutical Co (SZSE:301277) Headlines

No Headlines